In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Omeros Corp (OMER), with a price target of $32. The company’s shares opened today at $15.48.
McCarthy observed:
“Omeros reported 4Q18 with record Omidria revenues of $22M (in line with preliminary), operating expenses of $40M, net loss of ($23.5M). Omeros ended the period with $60.5M in cash and equivalents. The company also has a $50M accounts receivable line of credit. Our model has been adjusted for increasing expenses, offset by increasing revenue from Omidria; no change to PT.”
According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.0% and a 33.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Aridis Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Omeros Corp with a $33 average price target, representing an 113.2% upside. In a report issued on February 21, H.C. Wainwright also reiterated a Buy rating on the stock with a $34 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27 and a one-year low of $8.36. Currently, Omeros Corp has an average volume of 655.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.
